Aug. 17 at 5:48 PM
$QNTM just cleared a major regulatory hurdle — is the next phase about to get interesting? 🚀
FDA approval clears Lucid-MS to advance into a randomized, double-blind, placebo-controlled Phase 2 trial in progressive MS, while liquidity rose to US
$9.5M and operating expenses fell 53% year over year.
🔬 Lucid-MS Phase 2 cleared to proceed
💰 Liquidity sufficient to fund planned operations to at least October 2027
📉 Operating expenses down to US
$2.29M from US
$4.85M
Find more on QNTM here👉
https://www.zacks.com/stock/quote/QNTM?cid=sm-stocktwits-0-quote_overview-oc-39282&ADID=SYND_STOCKTWITS_TWEET_0_QUOTEOVERVIEW_OC_39282
